We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Uremic Toxin Removal With a New High Flux Cellulose Triacetate Membrane

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00230906
First Posted: October 3, 2005
Last Update Posted: December 28, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Nissho Nipro Europe
Information provided by:
University Hospital, Ghent
  Purpose
Comparison of the uremic toxin removal by haemodialysis either with a low flux or a new high flux cellulose triacetate membrane

Condition Intervention
Haemodialysis Procedure: Haemodialysis with either low or high flux membranes

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Uremic Toxin Removal With a New High Flux Cellulose Triacetate Membrane

Resource links provided by NLM:


Further study details as provided by University Hospital, Ghent:

Primary Outcome Measures:
  • Concentration of uremic components after 3 weeks of haemodialysis

Estimated Enrollment: 12
Study Start Date: January 2001
Study Completion Date: April 2002
Detailed Description:
Comparison of the uremic toxin removal by haemodialysis either with a low flux or a new high flux cellulose triacetate membrane
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Chronic haemodialysis patient
  • Serum albumin > 3.6 g/dl

Exclusion Criteria:

  • < 18 years
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00230906


Locations
Belgium
University Hospital Ghent
Ghent, Belgium, 9000
Sponsors and Collaborators
University Hospital, Ghent
Nissho Nipro Europe
Investigators
Principal Investigator: Raymond Van Holder, MD, PhD University Hospital, Ghent
  More Information

Additional Information:
ClinicalTrials.gov Identifier: NCT00230906     History of Changes
Other Study ID Numbers: 2001/182
First Submitted: September 29, 2005
First Posted: October 3, 2005
Last Update Posted: December 28, 2007
Last Verified: December 2007